# Suzhou Baimai Biopharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-baimai-biopharmaceutical-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Total disclosed funding: $7.4M
- Latest round: Series A (Sep 6, 2022)
- Investors on record: 2

## About

Established in 2019, Suzhou Baimai Biopharmaceutical Co., Ltd. is a pharmaceutical company focusing on the platform of biomaterial technology. Currently, it has realized the Lincese out business cooperation of an early product and has a self-initiated pipeline, BM201, approved for IND and about to enter Phase I clinical. The founder Zhuang Liu has been working in the field of biomaterials for more than ten years.

The company focuses on innovative drugs and agents for the treatment of diseases such as oncology and cancer and provides immunotherapy treatment options. The development pipeline includes the long-acting extended-release formulation BM201, the ICD-chemical combination formulations BM101 and BM221, and the multichannel immune agonist BM501.

## Funding rounds

- Series A, Sep 6, 2022 — YuanBio Venture
- Series A, Jul 30, 2022, $7.4M — LH Ventures

## Investors

- LH Ventures (https://capitalatlas.ai/funds/lh-ventures) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A